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It is not clearly understood why HPV infections resolve in certain individuals and result in more severe lesions in others. It is, however, revealed that an individual's susceptibility and other enabling factors such as immune status, nutrition, endogenous and exogenous hormones, tobacco smoking, high parity, prolonged use of oral contraceptives, genetic disorders, early sexual debut, uncircumcision of the male partner, and co-infection with other sexually transmitted agents such as HIV, herpes simplex virus type 2, and Chlamydia trachomatis play a role in the development of lesions. [5, 6] Worldwide, about 751 women die from cervical cancer daily and >80% of these deaths come from the Sub-Saharan Africa.
In Nigeria, 14,000-20,000 new cases are diagnosed every year, while 9659 deaths occur every year translating to the loss of 26 women every day. [7] This study was carried out to detect some hrHPVs that circulate in Kaduna State as this has not yet been reported and will improve the prospects on the establishment of cervical cancer screening program in the state. This will contribute enormously to the global efforts of prevention and control of HPV infection.
MaterIals and Methods

Study area, design, and population
The study was hospital-based and cross-sectional; conducted in three hospitals from the three senatorial zones of Kaduna State, Nigeria; Ahmadu Bello University Teaching Hospital (ABUTH), Zaria, representing Kaduna North, Barau Dikko Teaching Hospital (BDTH), Kaduna, representing Kaduna Central General Hospital (GH), Kafanchan, representing Kaduna South, in the year 2015.
Ethical approval was granted by the Health Research Ethics Committee of ABUTH, Zaria, as well as from the Kaduna State Ministry of Health, and informed consent (written) was obtained from the subjects before sample and data collection. The Human Experimentation Guideline as stated by Helsinki Declaration of 1975 (revised in 2000) was followed in the conduct of the research. A structured questionnaire was used to collect sociodemographic and clinical information from consenting women.
The study population comprised of all consented sexually active women, from age 15 years and above (including patients, caregivers, pregnant women, women with infertility issues, and women attending family planning clinic), attending the selected hospitals. Nonsexually active women as well as those that did not consent were excluded from the study.
Sample collection and processing
A prevalence rate of 21.6% for hrHPV from a previous study in Osun State, Nigeria, [8] was used to determine the sample size (276), using the equation derived by Sarmukaddam and Garad [9] at 95% confidence interval. A sterile cytobrush was used to collect the cervical scrapings (exfoliated cells from the squamocolumnar junction of the ecto and endocervix) of 276 women (92 women from each hospital) by a gynecologist. The brush was then rinsed in 5 ml phosphate-buffered saline and stored at −20°C in the gynecology department of the various hospitals until analyzed.
Screening of samples
All the 276 samples were screened for HPV antigen using enzyme-linked immunosorbent assay (HPV Antigen ELISA Kit in Cervical Swab, WKEA MED SUPPLIES, CHANGCHUN, CHINA) and squamous intraepithelial lesion (SIL) using Conventional Pap Smear technique as described by the University of Nottingham Medical School, Division of Histopathology. [10] Detection and genotyping of human papillomavirus DNA Out of the 276 samples screened, 24 were positive for HPV antigen and 17 were positive for SIL. A total of thirty samples positive for either HPV antigen or SIL, as well as those positive for both, were subjected to polymerase chain reaction (PCR) to detect the viral DNA and genotypes. The double-stranded DNA of HPV was extracted from the samples using QIAamp DNA Mini Kit (Qiagen, Germany), following manufacturer's protocol. The extracted DNA was used as template to generate copies that were amplified by conventional PCR technique, using first generic primer (MY095 ' -CGT CCA AGA GGA TAC TGA TC-3 ' and MY115 ' -GCC CAG GGT CAT AAC AAT GG-3 ' located at 450 bp) [11, 12] and subsequently specific primer sets for each hrHPV types16 (Forward: 5 ' -TCAAAGCCACTGTGTCCTGA-3 ' , R e v e r s e : 
, R e v e r s e : 5 ' -TTTTTTCCAGTGTCTCTCCA-3 ' , located at 236 bp) [11, 12] (Bioneer, Inc., United States of America). All procedures were carried out following the manufacturer's protocol. The amplification was done in a total volume of 25 µl mixture (12.5 µl of the Master mix which consists of PCR buffer, Deoxyribonucleotide triphosphates, or dNTP's and Taq polymerase, 2 µl each of forward and reverse primers, 2.5 µl of nuclease-free water, 0.3 µl of magnesium chloride or MgCl 2 , and 6 µl of template DNA). The tube containing the mixture was placed in a thermocycler (Veriti 96-well Thermal Cycler, Thermo Fisher Scientific, USA) which was programmed to run in three steps per cycle. Cycling conditions began with an initial 5 min denaturation step at 95°C for 5 min, followed by 35 cycles of denaturation (94°C, 30 s), annealing (58°C, 48°C, 55°C, 46°C, and 44°C for generic primer, HPV types 16, 18, 31, and 45 respectively, 30 s), and extension (72°C, 30 s). A final extension was done at 72°C for 7 min was performed at the end of the 35 cycles. The amplified products were then subjected to gel electrophoresis using 2% agarose gel at room temperature for size separation of PCR products. Amplicons were determined against a 50 bp molecular size marker DNA ladder (Bioneer, Inc., United States of America).
Data analysis
Data were analyzed using the frequency procedure of Statistical Analysis System version 9. The results obtained were further analyzed to see if there was any correlation between infection with hrHPV types and the development of SIL [ Table 2 ]. It was observed that there was a highly significant (P = 0.0001) association (r = 0.75) between infection with hrHPV types and the development of SIL.
dIscussIon
The prevalence of hrHPV in this study was 66.7% which shows that there is a high possibility of detecting DNA of hrHPV in women that are infected with HPV and those that have cervical dysplasia. It, therefore, means that HPV testing should not just stop at screening for the viral antigen, further effort should be made in checking if the person involved is infected with hrHPV or lrHPV. The obtained prevalence is lower than 76% reported in Kano State, Nigeria, [13] but much higher than those reported by Famooto et al. [14] and Fadahunsi et al., [8] all conducted in Nigeria. The prevalence is also higher than the 8.2% reported in rural India by Aggarwal et al. [15] and 16.1% in Paraguay. [16] The differences in the prevalence rate could also be due to differences in sociocultural habits of the people such as marriage practices, religious policies, diet, medical treatment options, and interpersonal relationships at the different regions. The difference could also be due to the different diagnostic methods used which include PCR, 21 HPV Geno array test kit, and Roche linear array HPV genotyping test.
Four hrHPV types were detected, some of which occurred singly and some in combination with other types. hrHPV was detected in 46.2% of women with normal cytology but positive for HPV. This could mean primary infection, re-infection, or persistent infection that has not gotten to the stage of causing cervical lesions. This category of women might develop cervical cancer if not monitored by continuous HPV screening and Pap smear test. In an earlier study with similar results, it was advised that such women should go for repeat Pap test in 6-12-month interval. [17] The prevalence rate obtained here is much lower 22.4% reported by Fadahunsi et al. [8] in Southern Nigeria.
The prevalence of hrHPV in women with abnormal cytology was 82.4%. This shows that most women that have cervical dysplasia are likely to be harboring the DNA of hrHPV. These women are, therefore, encouraged to go for a follow-up test and immediate treatment if need be. The obtained prevalence (11) 40% (12) 16.7% (5) 3.3% (1) 33.3% ( is much >22.7% reported in Osun State, Southern Nigeria, by Fadahunsi et al. [8] This difference in prevalence could be due to differences in the diagnostic methods used.
The prevalence of hrHPV in relation to SIL showed that HPV DNA was found in 1 of the 2 women that had ASC-US, 11 out of the 13 women that had LGSIL, and in the 2 women that had HGSIL. This implies that the possibility of detecting HPV DNA in a cervical lesion increases with the severity of the lesion. Women with ASC-US that were infected with hrHPV should have a repeat Pap smear within 6-12 months, while women with LGSIL or HGSIL that are infected with hrHPV should have immediate colposcopy and consequent treatment as the case may be. [17] Further analysis of the individual prevalence of each hrHPV type revealed that HPV type 16 had a prevalence of 55.0% which is much higher than the 15.8% reported in Kano State, Nigeria, [13] 9.2% reported in Abuja, Nigeria, [14] and 4.5% reported in Southern Italy by Ammatuna et al. [18] The prevalence of HPV 18 was 60.0% which is much higher than the 23.7% reported in Kano, Nigeria, [13] 10.8% reported in Abuja, Nigeria, [14] and 1.3% reported in South Italy. [18] The prevalence rate of HPV type 31 was 25.0% which is much >6.2% reported in Abuja, Nigeria [14] and 1.5% reported in South Italy. [18] The prevalence of HPV type 45 was 5.0% which is very much lower than the 13.9% reported in Abuja, Nigeria, [18] but much >0.6% reported in South Italy. [18] These differences in prevalence rates could indicate a different pattern of the distribution of HPV types that might reflect the geographic origins of samples. The difference could also be because this study screened only women that were positive for HPV antigen and cervical dysplasia other than the entire study population, which would have increased the chances of detecting the DNA of hrHPV. The higher prevalence of hrHPV obtained in this study as compared to other studies indicate that the study population is more at risk of cervical cancer; therefore, they should be encouraged to go for Pap smear screening more often and also to avoid exposure to other factors such as smoking, high parity, prolonged use of contraception, among others, that could promote cervical carcinogenesis.
HPV type 18 was the most common hrHPV type detected in this study area. This agrees with the report of Auwal et al. [13] in Kano State, Nigeria, but contrast the findings of Fadahunsi et al. [8] in Osun State, Nigeria, Molano et al. [19] in Columbia, Didelot-Rousseau et al. [20] in Burkina Faso, and Vidal et al. [21] in Tanzania that reported HPV 16 as the most common type. In Mozambique, HPV 35 was found to be slightly higher than HPV16. [22] HPV 52 was noted to be slightly more than HPV 16 or 35 in Kenya. [23] In Senegal, HPV16 and 58 were the most common in women with cervical lesions. [24] Human papillomavirus 45 was found to be the least prevalent in our study. These HPV types could cause cervical cancer in these different regions, and apart from HPV 16 and 18, none of the other HPV types have a vaccine that is already in circulation. It is, therefore, of importance that the Government put in place policies that will bring about the supply and utilization of the 9-valent vaccine (Gardasil 9) which was approved by the United States Food and Drug Administration (US FDA) for routine vaccination of males and females at age 11 or 12. [25] This vaccine protects against 7 hrHPV types (16, 18, 31, 33, 45, 52, and 58), which can prevent precancerous cervical abnormalities caused by these strains and 2 lrHPV types (6 and 11). [26, 27] About 25.0% (5/20) of the study population were infected with both HPV type 16 and type 18. This is much lower than 60.5% reported in Kano State, Nigeria, by Auwal et al. [13] and but much higher the 0.5% co-infection rate reported in Southern Italy. [18] HPV types 16 and 18 have been reported to account for 70% cases if invasive cervical cancers worldwide. [4] Co-infection of these two HR types places an individual more at risk of developing cancer than infection with either of the two types. [4] Co-relational analysis of the result of hrHPV and SIL revealed a strong positive correlation between infection with hrHPV types and the development of SIL. This implies that an increase in hrHPV infection will lead to a direct increase in SIL and it further affirms existing reports that persistent infection with hrHPV's leads to the development of SIL.
conclusIon
The findings from this study have shown that there is a high 
Recommendations
1. Further studies should be done using molecular screening techniques such as the Linear Array® HPV Genotyping (Roche Molecular Diagnostics, Pleasanton, CA, USA), Clinical arrays® HPV (Genomica SAU, Madrid, Spain), and the CLART ® Human Papillomavirus 2 (Genomica, Madrid, Spain), which have the capacity to detect up 37 HPV types be adopted so as to detect a wide range of HPV types in the study area 2. Currently, there are just two vaccines in circulation in the study area, which protects against infection with HPV type 16, 18, 6, and 11. Therefore, detecting HPV type 31 and 45 in the study area emphasizes the need for the government to put in place, policies that will bring about the supply and utilization of the 9-valent vaccine (Gardasil 9) which was approved by the US FDA as this vaccine protects against these two types.
Limitation of the study
HPV genotyping was done using only four type-specific primer sets, although they were selected because of the high prevalence of those types; nonetheless, there could be other hrHPV types that circulate in the state, which were not detected. providing the storage facility for the samples collected. We owe a big gratitude to our respondents for accepting to participate in this study.
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